Skip to content


Our model for value creation

Our model for value creation highlights how Servier generates tangible and intangible advantages for all of its stakeholders, integrating sustainability and financial performance with a holistic approach. 

Our governance model

Governed by a Foundation and free from shareholder pressure, Servier can fully focus on its vocation as a Group committed to therapeutic progress to serve patient needs.

all about servier

Our presence throughout the world

Our medicines are available in over 150 countries. Pursuing our vocation, we bolster our presence in regions where patient needs are greatest.


Over 150 countries where the Group’s medicines are distributed


production sites


research centers and 3 hubs with 15 clinical development centers

all about servier

High-performing R&D to serve patient needs

Our ambition is clear: to strengthen our leadership position in select therapeutic areas, especially cancers and rare diseases.

To achieve this, our teams are focusing their research efforts, leveraging open innovation and AI.

all about servier

Our ambition for 2030

Our 2030 strategy fulfils our vocation and takes account of the health challenges facing society today and into the future. We are driven to achieve our ambition as cancer is ever-more prevalent and cardiometabolic diseases still represent a major cause of death around the world.

all about servier

Making a meaningful social impact for patients and a sustainable world

The notion of corporate social responsibility (CSR) permeates every area of our corporate strategy. It is at the heart of our Servier 2030 ambition.

Download the 2022-2023 Integrated Annual Report

Download the 2022-2023 Integrated Annual Report